Bio Capital Surpluse from 2010 to 2024

TECH Stock  USD 71.28  0.23  0.32%   
Bio Techne's Capital Surpluse is increasing with slightly volatile movements from year to year. Capital Surpluse is estimated to finish at about 871.3 M this year. For the period between 2010 and 2024, Bio Techne, Capital Surpluse quarterly trend regression had mean deviation of  233,974,076 and range of 742 M. View All Fundamentals
 
Capital Surpluse  
First Reported
2010-09-30
Previous Quarter
715.1 M
Current Value
721.5 M
Quarterly Volatility
193.8 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Bio Techne financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bio Techne's main balance sheet or income statement drivers, such as Depreciation And Amortization of 117.3 M, Total Revenue of 1.2 B or Gross Profit of 811.7 M, as well as many indicators such as Price To Sales Ratio of 6.9, Dividend Yield of 0.0042 or PTB Ratio of 6.78. Bio financial statements analysis is a perfect complement when working with Bio Techne Valuation or Volatility modules.
  
Check out the analysis of Bio Techne Correlation against competitors.

Latest Bio Techne's Capital Surpluse Growth Pattern

Below is the plot of the Capital Surpluse of Bio Techne Corp over the last few years. It is Bio Techne's Capital Surpluse historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Bio Techne's overall financial position and show how it may be relating to other accounts over time.
Capital Surpluse10 Years Trend
Slightly volatile
   Capital Surpluse   
       Timeline  

Bio Capital Surpluse Regression Statistics

Arithmetic Mean379,396,508
Geometric Mean297,759,081
Coefficient Of Variation71.69
Mean Deviation233,974,076
Median246,568,000
Standard Deviation271,978,040
Sample Variance73972.1T
Range742M
R-Value0.94
Mean Square Error9376.4T
R-Squared0.88
Slope57,125,032
Total Sum of Squares1035608.8T

Bio Capital Surpluse History

2024871.3 M
2023829.8 M
2022721.5 M
2021653.7 M
2020534.4 M
2019420.5 M
2018316.8 M

About Bio Techne Financial Statements

Investors use fundamental indicators, such as Bio Techne's Capital Surpluse, to determine how well the company is positioned to perform in the future. Although Bio Techne's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Capital Surpluse829.8 M871.3 M

Currently Active Assets on Macroaxis

When determining whether Bio Techne Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bio Techne's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bio Techne Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bio Techne Corp Stock:
Check out the analysis of Bio Techne Correlation against competitors.
You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Techne. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Techne listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.32)
Dividend Share
0.32
Earnings Share
0.95
Revenue Per Share
7.424
Quarterly Revenue Growth
0.045
The market value of Bio Techne Corp is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Techne's value that differs from its market value or its book value, called intrinsic value, which is Bio Techne's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Techne's market value can be influenced by many factors that don't directly affect Bio Techne's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bio Techne's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Techne is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Techne's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.